首页> 中文期刊> 《中外医疗》 >肝癌患者凝血四项指标联合检测分析

肝癌患者凝血四项指标联合检测分析

         

摘要

目的:分析肝癌凝血4项指标联合检测的意义。方法选择2015年2—10月该院肝癌患者30例,另纳入同期健康人30例。对比凝血4项检测结果。结果肝癌患者FBG为(2.6±0.3)g/L,显著低于健康对照组,PT时间为(20.5±1.6)s,APTT为(42.3±1.5)s,TT为(18.1±0.5)s,显著高于对照组(P﹤0.05)。凝血4项指标检出阳性率分别为30.00%(20/60),26.67%(18/60),46.67%(28/60),23.33%(16/60),显著高于对照组(P﹤0.05)。结论重视对肝癌患者凝血4项的联合检测可对凝血状况、肝脏受损程度作出准确分析。%Objective To analyze the significance of combined detection of four blood coagulation indexes in patients with liver cancer. Methods 30 cases of patients with liver cancer treated in our hospital from February 2015 to October 2015 were selected, and 30 healthy people treated at the same period were selected, and the detection results of four blood coagu-lation indexes were compared. Results The FBG of patients with liver cancer was (2.6±0.3) g/L, which was obviously lower than that of the control group, the PT time, APTT and TT of the patients with liver cancer were respectively (20.5±1.6) s, (42.3±1.5) s and (18.1±0.5) s, which were obviously higher than those in the control group (P<0.05), the detection positive rates of four blood coagulation indexes of the patients with liver cancer were respectively 30.00% (20/60), 26.67% (18/60), 46.67% (28/60) and 23.33% (16/60), which were obviously higher than those of the control group(P<0.05). Conclusion It can accurately analyze the blood coagulation condition and liver damage degree to pay attention to the combined detection of four blood coagulation indexes in patients with liver cancer.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号